BioNumerik Pharmaceuticals Appoints Steve Carchedi to Board of Directors

SAN ANTONIO, June 14, 2012 /PRNewswire/ -- BioNumerik Pharmaceuticals, Inc. ("BioNumerik") today announced the appointment of Mr. Steve Carchedi to BioNumerik's Board of Directors.

Mr. Carchedi brings extensive pharmaceutical industry and oncology product commercialization experience to the BioNumerik Board. During his more than 29 years in the pharmaceutical industry, he has held key positions in several multi-national pharmaceutical companies and led the commercialization of multiple oncology products that are on the market today as the standard of care.

"Adding Steve to our Board is an important step for BioNumerik as we work to advance our two distinct oncology Phase III product candidates towards potential commercialization," said Frederick H. Hausheer, M.D., Chairman & Chief Executive Officer of BioNumerik Pharmaceuticals. "This is an important and exciting time for BioNumerik, and Steve's experience and insight in commercializing new oncology pharmaceuticals will be of great value."

Mr. Carchedi is currently Chief Marketing Officer for General Electric (GE) Healthcare-MDx where he is responsible for leading worldwide marketing for GE's Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson. Mr. Carchedi also held the position of Global Marketing Leader for Johnson & Johnson Oncology, where he led the worldwide product launch of VELCADE® (Bortezomib). Before joining Johnson & Johnson, Mr. Carchedi played a key role in commercializing the oncology portfolio at Eli Lilly & Company, including GEMZAR® (Gemcitabine), and in commercializing leading oncology chemotherapies at Bristol Myers Squibb, including TAXOL® (Paclitaxel) and PARAPLATIN® (Carboplatin).

Currently, Mr. Carchedi serves on the Strategic Advisory Board for PCAsso Diagnostics LLC and also serves as Co-Chair of the BioNJ Personalized Medicine & Diagnostics Committee. He is a member of the Chief Marketing Officer Council (CMOC), the Ontario Institute of Cancer Research Commercial Committee (OICR) and served on the Pharmaceutical Industry Board of the American Pediatric Family Foundation. Mr. Carchedi received a B.S. in Marketing from West Chester University and an MBA in Marketing from Drexel University.

Mr. Carchedi joins current BioNumerik board members Frederick H. Hausheer, M.D. (Chairman & Chief Executive Officer), Harry R. Jacobson, M.D., James R. Leininger, M.D., Homer L. Pearce, Ph.D., Dennert O. Ware, and John W. Yarbro, M.D., Ph.D.

About BioNumerik:

BioNumerik Pharmaceuticals, Inc., based in San Antonio, Texas, is focused on the discovery, development and commercialization of novel drugs for the treatment of cancer and cancer supportive care. BioNumerik currently has two self-originated oncology-focused drug candidates, Tavocept™ and Karenitecin®, in Phase III clinical development. BioNumerik has seven additional drug discovery research programs, and has generated a patent portfolio of more than 500 patents and pending patent applications worldwide.

Editor's Note: This release is also available at: www.bionumerik.com

Contact:
David R. Margrave, Chief Administrative Officer
BioNumerik Pharmaceuticals, Inc.
Public Relations Department
(210) 614-1701, ext. 500
email: [email protected]

SOURCE BioNumerik Pharmaceuticals, Inc.